[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Article
July 14, 1962

Oral Prolonged-Action Medication

Author Affiliations

Ottawa, Canada

JAMA. 1962;181(2):102-105. doi:10.1001/jama.1962.03050280032005b
Abstract

THERE ARE OBVIOUS ADVANTAGES to the physician if he is able to prescribe certain drugs in preparations which in one dose contain a sufficient amount of medication to last all day or all night. Although enteric-coated tablets probably represent the first attempt to alter the release of drugs, a variety of drugs are available now in prolonged, sustained, delayed, repeat-action, and timed-release dosage forms. Enthusiastic advertisements for some of these products, which may be generally considered as having prolonged-action, purport to describe just when and how much of a drug is released, and simplified curves of blood levels or clinical response claim to depict how the preparation will act in vivo. Since these products usually contain the equivalent of 3 normal doses of the drug, it is of considerable importance to the physician to know that the drug will actually be released in the advertised manner and not released either

References
1.
Dragstedt, C. A.:  Oral Medication with Preparations for Prolonged Action ,  JAMA 168:1652-1655 ( (Nov. 22) ) 1958.Crossref
2.
Lazarus, J., and Cooper, J.:  Oral Prolonged Action Medicaments: Their Pharmaceutical Control and Therapeutic Aspects ,  J Pharm Pharmacol 11:257-290 ( (May) ) 1959.Crossref
3.
Nelson, E.: Long Acting Oral Products in Remington's Practice of Pharmacy, 1960.
4.
Lazarus, J., and Cooper, J.:  Absorption, Testing, and Clinical Evaluation of Oral Prolonged-Action Drugs ,  J Pharm Sci 50:715-732 ( (Sept.) ) 1961.Crossref
5.
Morrison, A. B.; Perusse, C. B.; and Campbell, J. A.:  Physiologic Availability and In Vitro Release of Riboflavin in Sustained-Release Vitamin Preparations ,  New Engl J Med 263:115-119 ( (July 21) ) 1960.Crossref
6.
Beecher, H. K.:  Powerful Placebo ,  JAMA 159:1602-1606 ( (Dec. 24) ) 1955.Crossref
7.
Modell, W.:  Problems in Evaluation of Drugs in Man ,  J Pharm Pharmacol 11:577-594 ( (Oct.) ) 1959.Crossref
8.
Modell, W.:  Sensitivity and Validity of Drug Evaluations in Man ,  Clin Pharmacol Ther 1:769-776 ( (Nov.) -Dec.) 1960.
9.
Loranger, A. W.; Prout, C. T.; and White, M. A.:  Placebo Effect in Psychiatric Drug Research ,  JAMA 176:920-925 ( (June 17) ) 1961.Crossref
10.
Modell, W., and Houde, R. W.:  Factors Influencing Clinical Evaluation of Drugs ,  JAMA 167:2190-2199 ( (Aug. 30) ) 1958.Crossref
11.
Chapman, D. G.; Crisafio, R.; and Campbell, J. A.:  Relation Between In Vitro Disintegration Time of Sugar-Coated Tablets and Physiological Availability of Riboflavin ,  J Amer Pharm Ass (Scient. Ed.) 43:297-304 ( (May) ) 1954.Crossref
12.
Chapman, D. G.; Crisafio, R.; and Campbell, J. A.:  Relation Between In Vitro Disintegration Time of Sugar-Coated Tablets and Physiological Availability of Sodium p-Aminosalicylate ,  J Amer Pharm Ass 45:374-378 ( (June) ) 1956.Crossref
13.
Morrison, A. B.; Chapman, D. G.; and Campbell, J. A.:  Further Studies on Relation Between In Vitro Disintegration Time of Tablets and Urinary Excretion Rates of Riboflavin ,  J Amer Pharm Ass 48:634-637 ( (Nov.) ) 1959.Crossref
14.
Morrison, A. B., and Campbell, J. A.:  Relationship Between Physiological Availability of Salicylates and Riboflavin and In Vitro Disintegration Time of Enteric Coated Tablets ,  J Amer Pharm Ass 49:473-478 ( (July) ) 1960.Crossref
15.
Blythe, R. H.:  Formulation and Evaluation of Sustained Release Products ,  Drug Stand 26:1-7 ( (Jan.) -Feb.) 1958.
16.
Campbell, J. A.; Chapman, D. G.; and Chatten, L. G.:  Timed Disintegration Medication—Need for More Quantitative Criteria ,  Canad Med Ass J 77:602-603 ( (Sept. 15) ) 1957.
17.
Levy, G.:  Comparison of Dissolution and Absorption Rates of Different Commercial Aspirin Tablets ,  J Pharm Sci 50:388-392 ( (May) ) 1961.Crossref
18.
Wagner, J. G.:  Biopharmaceutics: Absorption Aspects ,  J Pharm Sci 50:359-387 ( (May) ) 1961.Crossref
19.
Shenoy, K. G.; Chapman, D. G.; and Campbell, J. A.:  Sustained Release in Pelleted Preparations as Judged by Urinary Excretion and In Vitro Methods ,  Drug Stand 27:77-84 ( (May) -June) 1959.
20.
Chapman, D. G.; Shenoy, K. G.; and Campbell, J. A.:  Sustained Release of Drug-Resin Complexes as Judged by Urinary Excretion Rates ,  Canad Med Ass J 81:470-477 ( (Sept. 15) ) 1959.
21.
Lozinski, E.:  Physiological Availability of Dicumarol ,  Canad Med Ass J 83:177-178 ( (July 23) ) 1960.
22.
Levy, G., and Nelson, E.:  Pharmaceutical Formulation and Therapeutic Efficacy ,  JAMA 177:689-691 ( (Sept. 9) ) 1961.Crossref
×